AstraZeneca to exit specialist areas
This article was originally published in Scrip
Executive Summary
AstraZeneca is to stop research in several core areas as it strives to improve its R&D efficiency and cut costs. Newly released details of the restructuring, which was first revealed at its financial results meeting in January, show that it will also include a number of site closures worldwide.